Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AIFF · NASDAQ · Services-Prepackaged Software
Firefly Neuroscience (AIFF) · oqro.io/stocks/AIFF · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.935−0.0286 (−2.97%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
−41.6% (−$0.665) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.60 on Nov 13, 2025 to $0.935 on Nov 13, 2026 (−41.6%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Services-Prepackaged Software company based in Kenmore, Ny.
Last 12 months
−41.6%
Market value
$14.7M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 554K shares sold short (3.5% of shares outstanding), −26.3% vs the previous count, 5.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$514K
+71.9% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $9.23M, at Jun 30, 2026
Net income, last 12 months
−$9.11M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Dec 4, 2024.
Revenue, fiscal 2025
$1.14M
+957.4% vs the year before
Net income, fiscal 2025
−$19.9M
A loss for the year
Shares outstanding
15.7M
As of Aug 4, 2026
Traded Oct 20 – Oct 22, 2025 · largest single transaction ~$162KNot reported under a pre-arranged trading plan
Oct 22, 2025~$162K · 78K sh @ $2.07
DetailsOfficial recordOct 20, 2025~$82K · 34K sh @ $2.46
DetailsOfficial recordOct 21, 2025~$46K · 19K sh @ $2.40
DetailsOfficial recordTraded Oct 16 – Oct 17, 2025 · largest single transaction ~$115KNot reported under a pre-arranged trading plan
Oct 17, 2025~$115K · 45K sh @ $2.55
DetailsOfficial recordOct 16, 2025~$106K · 40K sh @ $2.65
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No open-market purchase by an insider of Firefly Neuroscience was filed in the last 90 days. The latest on record was on Sep 29, 2023.
Since 2010, Firefly Neuroscience insiders reported 120 open-market purchases and 13 sales on Forms 4 and 5, with purchases in 9 different years, most recently 2023.
No open-market sale by an insider of Firefly Neuroscience (AIFF) was filed with the SEC in the last 90 days.
No trade in Firefly Neuroscience (AIFF) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Insiders of Firefly Neuroscience reported 120 open-market purchases and 13 sales since 2010; purchases in 9 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $1.02M10×10 trades |
| 2023 | $175K1×1 trade | — |
| 2022 | $409K98×98 trades | — |
| 2021 | — | $998K2×2 trades |
| 2019 | $19K4×4 trades | — |
| 2018 | — | $4.2K1×1 trade |
| 2017 | $1.7K1×1 trade | — |
| 2016 | $27K3×3 trades | — |
| 2014 | $14K5×5 trades | — |
| 2013 | $29K3×3 trades | — |
| 2012 | $7501×1 trade | — |
| 2010 | $8K4×4 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last results
Dec 4, 2024
More than 30 days ago
Next results, expected
Not announced
Purchases after results
48%
57 of 120 insider purchases since 2004 came within 30 days after a results announcement
From Firefly Neuroscience's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Firefly Neuroscience's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Top officer leaving
“On September 8, 2026, the board of directors (the “Board”) of Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), terminated Paul Krzywicki as Chief Financial Officer of the Company, effective September 24, 2026.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.